321 related articles for article (PubMed ID: 38727005)
1. Development of small molecule drugs targeting immune checkpoints.
Chen L; Zhao X; Liu X; Ouyang Y; Xu C; Shi Y
Cancer Biol Med; 2024 May; 21(5):382-99. PubMed ID: 38727005
[TBL] [Abstract][Full Text] [Related]
2. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
[TBL] [Abstract][Full Text] [Related]
3. If small molecules immunotherapy comes, can the prime be far behind?
Zhang J; Zhang Y; Qu B; Yang H; Hu S; Dong X
Eur J Med Chem; 2021 Jun; 218():113356. PubMed ID: 33773287
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Qiu J; Cheng Z; Jiang Z; Gan L; Zhang Z; Xie Z
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791528
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
6. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
[TBL] [Abstract][Full Text] [Related]
7. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
9. Non-coding RNA and immune-checkpoint inhibitors: friends or foes?
Shek D; Read SA; Akhuba L; Qiao L; Gao B; Nagrial A; Carlino MS; Ahlenstiel G
Immunotherapy; 2020 May; 12(7):513-529. PubMed ID: 32378480
[TBL] [Abstract][Full Text] [Related]
10. The role of extracellular vesicle immune checkpoints in cancer.
Zhang W; Ou M; Yang P; Ning M
Clin Exp Immunol; 2024 May; 216(3):230-239. PubMed ID: 38518192
[TBL] [Abstract][Full Text] [Related]
11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
13. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
14. Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development.
Sasikumar PG; Ramachandra M
Front Immunol; 2022; 13():752065. PubMed ID: 35585982
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks.
Meng L; Wu H; Wu J; Ding P; He J; Sang M; Liu L
Cell Death Dis; 2024 Jan; 15(1):3. PubMed ID: 38177102
[TBL] [Abstract][Full Text] [Related]
16. NK Cell-Based Immune Checkpoint Inhibition.
Khan M; Arooj S; Wang H
Front Immunol; 2020; 11():167. PubMed ID: 32117298
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events.
Meybodi SM; Farasati Far B; Pourmolaei A; Baradarbarjastehbaf F; Safaei M; Mohammadkhani N; Samadani AA
Med Oncol; 2023 Jul; 40(8):243. PubMed ID: 37453930
[TBL] [Abstract][Full Text] [Related]
18. Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy.
Lee J; Han Y; Wang W; Jo H; Kim H; Kim S; Yang KM; Kim SJ; Dhanasekaran DN; Song YS
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439774
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
20. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]